EU/3/18/2071

About

On 26 October 2018, orphan designation (EU/3/18/2071) was granted by the European Commission to Loxo Oncology Limited, United Kingdom, for 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (also known as LOXO-292) for the treatment of medullary thyroid carcinoma.

Key facts

Active substance
6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
Disease / condition
Treatment of medullary thyroid carcinoma
Date of decision
26/10/2018
Outcome
Positive
Orphan decision number
EU/3/18/2071

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

First Floor, Templeback
10 Temple Back
Bristol BS1 6FL
United Kingdom
Tel. +44 (0)1494 957 372
E-mail: info@loxooncology.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating